SA’s medicines regulator says it does not anticipate suspending use of the Johnson & Johnson (J&J) coronavirus vaccine after US authorities warned earlier this week of a possible association with a rare neurological condition called Guillain-Barre syndrome.

The J&J shot is one of two vaccines being administered in the national coronavirus inoculation drive and is central to the government’s plans to reach 70% of the adult population by March 2022...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now